Buspirone in the treatment of schizophrenia

Buspirone as an adjunct to Risperidone for chronic schizophrenia: A double-blind, randomized, placebo-controlled study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT138712051556N8

Enrollment

Registered

2009-03-14

Start date

2006-04-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia. Schizophrenia

Interventions

Intervention 1: Tablet Risperidone (6 mg/day) combined with 60 mg/day of Tablets Buspirone as intervention group for 8 weeks. Intervention 2: Tablets Risperidone (6 mg/day) combined with Tablets plac

Treatment - Drugs

Tablet Risperidone (6 mg/day) combined with 60 mg/day of Tablets Buspirone as intervention group for 8 weeks

Tablets Risperidone (6 mg/day) combined with Tablets placebo as control group for 8 weeks

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Age between 18-55, Diagnosis of Schizophrenia based on DSM IV 3 chronic Schizophrenia, Minimum Score of 60 on Positive and Negative Scale Exclusion Criteria: Substance dependence, Pregnancy and breast feeding, Any medical problem

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of schizophrenia. Timepoint: Baseline and weeks 2-4-6-8 after beginig of treatment. Method of measurement: Positive and Negative Syndrome Scale (PANSS).	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 30, 2026